JPWO2021222153A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021222153A5 JPWO2021222153A5 JP2022565827A JP2022565827A JPWO2021222153A5 JP WO2021222153 A5 JPWO2021222153 A5 JP WO2021222153A5 JP 2022565827 A JP2022565827 A JP 2022565827A JP 2022565827 A JP2022565827 A JP 2022565827A JP WO2021222153 A5 JPWO2021222153 A5 JP WO2021222153A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- methyl
- pyridazine
- carboxamide
- methoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 125000005842 heteroatom Chemical group 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 21
- 229910052717 sulfur Inorganic materials 0.000 claims 21
- -1 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Chemical compound 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 19
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 15
- 125000002950 monocyclic group Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 14
- 150000002431 hydrogen Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- TUZYHKNFHIUFLC-FIBGUPNXSA-N 6-[(5-cyanopyrazin-2-yl)amino]-4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NC=C(C#N)N=C1)=O TUZYHKNFHIUFLC-FIBGUPNXSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- SPZMGFVHKBXPLJ-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(C#N)=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(C#N)=C1)=O SPZMGFVHKBXPLJ-FIBGUPNXSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VIDXTMKQKKGQTR-FIBGUPNXSA-N 4-(2-methoxy-3-pyrimidin-2-ylanilino)-N-(trideuteriomethyl)-6-[[6-(trifluoromethyl)pyridazin-3-yl]amino]pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CC=C(C(F)(F)F)N=N1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O VIDXTMKQKKGQTR-FIBGUPNXSA-N 0.000 claims 1
- RPSUMUABZNMGFC-HPRDVNIFSA-N 4-(5-fluoro-2-methoxy-3-pyrimidin-2-ylanilino)-6-[[4-(2-hydroxypropan-2-yl)pyridin-2-yl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NC=CC(C(C)(C)O)=C1)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O RPSUMUABZNMGFC-HPRDVNIFSA-N 0.000 claims 1
- DZAISLXLRKWMBD-HPRDVNIFSA-N 4-(5-fluoro-2-methoxy-3-pyrimidin-2-ylanilino)-6-[[5-(2-hydroxypropan-2-yl)pyridin-2-yl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NC=C(C(C)(C)O)C=C1)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O DZAISLXLRKWMBD-HPRDVNIFSA-N 0.000 claims 1
- SLLHVWKUZJYDQW-FIBGUPNXSA-N 4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-6-(pyridin-2-ylamino)-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NC=CC=C1)=O SLLHVWKUZJYDQW-FIBGUPNXSA-N 0.000 claims 1
- KEAUHMPUEXGRIL-BMSJAHLVSA-N 4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-6-[(6-methylpyridazin-3-yl)amino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CC=C(C)N=N1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O KEAUHMPUEXGRIL-BMSJAHLVSA-N 0.000 claims 1
- SAEFZUQERBNNNT-HPRDVNIFSA-N 4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-6-[[4-(2-hydroxypropan-2-yl)pyridin-2-yl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NC=CC(C(C)(C)O)=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O SAEFZUQERBNNNT-HPRDVNIFSA-N 0.000 claims 1
- RHUGMLIRIKGJRF-HPRDVNIFSA-N 4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-6-[[5-(2-hydroxypropan-2-yl)pyrazin-2-yl]amino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NC=C(C(C)(C)O)N=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O RHUGMLIRIKGJRF-HPRDVNIFSA-N 0.000 claims 1
- MPAIDNHXRDPHNT-FIBGUPNXSA-N 4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-N-(trideuteriomethyl)-6-[[6-(trifluoromethyl)pyridazin-3-yl]amino]pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CC=C(C(F)(F)F)N=N1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O MPAIDNHXRDPHNT-FIBGUPNXSA-N 0.000 claims 1
- HVMQBKCJEOLQJM-BMSJAHLVSA-N 4-[3-[5-[acetyl(methyl)amino]pyrazin-2-yl]-2-methoxyanilino]-6-(cyclopropanecarbonylamino)-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(N(C)C(C)=O)N=C2)=C1OC)=O HVMQBKCJEOLQJM-BMSJAHLVSA-N 0.000 claims 1
- BSJMLESGJKWBGG-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-(2-methoxy-3-pyrimidin-2-ylanilino)-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=NC=C(C(=O)NC([2H])([2H])[2H])C(=C1)NC1=C(C(=CC=C1)C1=NC=CC=N1)OC BSJMLESGJKWBGG-FIBGUPNXSA-N 0.000 claims 1
- XKYXPSHUPFBKEU-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-(5-fluoro-2-methoxy-3-pyrimidin-2-ylanilino)-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O XKYXPSHUPFBKEU-FIBGUPNXSA-N 0.000 claims 1
- KSSADOYRTUNEDM-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-(5-fluoro-2-methoxy-3-pyrimidin-2-ylanilino)-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=NC=C(C(=O)NC([2H])([2H])[2H])C(=C1)NC1=C(C(=CC(=C1)F)C1=NC=CC=N1)OC KSSADOYRTUNEDM-FIBGUPNXSA-N 0.000 claims 1
- XRWVUYRJQUAYSL-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(4-methoxypyrimidin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=CC(=N1)OC)OC XRWVUYRJQUAYSL-FIBGUPNXSA-N 0.000 claims 1
- HVJSTZSKSAPNDP-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(4-methyl-5-oxopyrazin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C(N=C2)=CN(C)C2=O)=C1OC)=O HVJSTZSKSAPNDP-FIBGUPNXSA-N 0.000 claims 1
- GKHGVNLHTJTHHE-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-methoxypyrazin-2-yl)anilino]-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=NC=C(C(=O)NC([2H])([2H])[2H])C(=C1)NC1=C(C(=CC=C1)C1=NC=C(N=C1)OC)OC GKHGVNLHTJTHHE-FIBGUPNXSA-N 0.000 claims 1
- AKROLHBODHQJQB-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-methoxypyrimidin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=C(C=N1)OC)OC AKROLHBODHQJQB-FIBGUPNXSA-N 0.000 claims 1
- QEFXBBGNUZPWAR-BMSJAHLVSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-methylpyrazin-2-yl)anilino]-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=NC=C(C(=O)NC([2H])([2H])[2H])C(=C1)NC1=C(C(=CC=C1)C1=NC=C(N=C1)C)OC QEFXBBGNUZPWAR-BMSJAHLVSA-N 0.000 claims 1
- FRYJARBJFRUEJK-BMSJAHLVSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-methylpyrimidin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=C(C=N1)C)OC FRYJARBJFRUEJK-BMSJAHLVSA-N 0.000 claims 1
- PXVMCZGTWIASMK-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-methylsulfonylpyrimidin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2S(C)(=O)=O)=C1OC)=O PXVMCZGTWIASMK-FIBGUPNXSA-N 0.000 claims 1
- STRAZDQVYCBSJC-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-morpholin-4-ylpyrazin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(N3CCOCC3)N=C2)=C1OC)=O STRAZDQVYCBSJC-FIBGUPNXSA-N 0.000 claims 1
- UOAQOZRJEGBCIB-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-morpholin-4-ylpyrimidin-2-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2N2CCOCC2)=C1OC)=O UOAQOZRJEGBCIB-FIBGUPNXSA-N 0.000 claims 1
- QFOMGIXDOQDXJW-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(5-morpholin-4-ylpyrimidin-2-yl)anilino]-N-(trideuteriomethyl)pyridine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2N2CCOCC2)=C1OC)=C1)=CN=C1NC(C1CC1)=O)=O QFOMGIXDOQDXJW-FIBGUPNXSA-N 0.000 claims 1
- CPPQJXUUHRZJSG-BMSJAHLVSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-[5-(1,1,1-trifluoro-2-hydroxypropan-2-yl)pyrimidin-2-yl]anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=C(C=N1)C(C(F)(F)F)(C)O)OC CPPQJXUUHRZJSG-BMSJAHLVSA-N 0.000 claims 1
- GAAIEYYYNWCLMI-BMSJAHLVSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-[5-(methylcarbamoyl)pyrazin-2-yl]anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(NC)=O)N=C2)=C1OC)=O GAAIEYYYNWCLMI-BMSJAHLVSA-N 0.000 claims 1
- BCXALXOKBDUYOV-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-[5-(oxolan-3-yl)pyrimidin-2-yl]anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C3COCC3)C=N2)=C1OC)=O BCXALXOKBDUYOV-FIBGUPNXSA-N 0.000 claims 1
- CKOBMYPPMKMVNN-HPRDVNIFSA-N 6-(cyclopropanecarbonylamino)-4-[3-[5-(2-hydroxypropan-2-yl)pyrazin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=C(N=C1)C(C)(C)O)OC CKOBMYPPMKMVNN-HPRDVNIFSA-N 0.000 claims 1
- YICKYLBZLUTENS-HPRDVNIFSA-N 6-(cyclopropanecarbonylamino)-4-[3-[5-(2-hydroxypropan-2-yl)pyridin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=C(C=C1)C(C)(C)O)OC YICKYLBZLUTENS-HPRDVNIFSA-N 0.000 claims 1
- JTHSHTJUGJKWSN-HPRDVNIFSA-N 6-(cyclopropanecarbonylamino)-4-[3-[5-(2-hydroxypropan-2-yl)pyrimidin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC=C1)C1=NC=C(C=N1)C(C)(C)O)OC JTHSHTJUGJKWSN-HPRDVNIFSA-N 0.000 claims 1
- YLRQXUZPTBECSM-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[3-[5-(3-hydroxyoxolan-3-yl)pyrazin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C3(COCC3)O)N=C2)=C1OC)=O YLRQXUZPTBECSM-FIBGUPNXSA-N 0.000 claims 1
- WFSPKBNFNNJFIS-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[3-[5-(3-hydroxyoxolan-3-yl)pyrimidin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C3(COCC3)O)C=N2)=C1OC)=O WFSPKBNFNNJFIS-FIBGUPNXSA-N 0.000 claims 1
- LVGTWWRMVUDQBJ-FIBGUPNXSA-N 6-(cyclopropanecarbonylamino)-4-[3-[5-[cyclopropyl(methyl)carbamoyl]pyrimidin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2C(N(C)C2CC2)=O)=C1OC)=O LVGTWWRMVUDQBJ-FIBGUPNXSA-N 0.000 claims 1
- WNOFBBGAGJRITM-HPRDVNIFSA-N 6-(cyclopropanecarbonylamino)-4-[5-fluoro-3-[5-(2-hydroxypropan-2-yl)pyrimidin-2-yl]-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound C1(CC1)C(=O)NC1=CC(=C(N=N1)C(=O)NC([2H])([2H])[2H])NC1=C(C(=CC(=C1)F)C1=NC=C(C=N1)C(C)(C)O)OC WNOFBBGAGJRITM-HPRDVNIFSA-N 0.000 claims 1
- NRWKHOASWFPTHU-FIBGUPNXSA-N 6-[(6-cyanopyridazin-3-yl)amino]-4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CC=C(C#N)N=N1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O NRWKHOASWFPTHU-FIBGUPNXSA-N 0.000 claims 1
- KVAUIMBUDNVEQZ-FIBGUPNXSA-N 6-[(6-cyclopropylpyridazin-3-yl)amino]-4-[3-(5-fluoropyrimidin-2-yl)-2-methoxyanilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CC=C(C2CC2)N=N1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O KVAUIMBUDNVEQZ-FIBGUPNXSA-N 0.000 claims 1
- HXALKVNBVPAHOZ-FIBGUPNXSA-N 6-[(6-methoxypyridazin-3-yl)amino]-4-(2-methoxy-3-pyrimidin-2-ylanilino)-N-(trideuteriomethyl)pyridazine-3-carboxamide Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(N=N1)=CC=C1OC)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O HXALKVNBVPAHOZ-FIBGUPNXSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- SSKBWUYEDGTVMU-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC(N=CN1C)=CC1=O)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC(N=CN1C)=CC1=O)=O SSKBWUYEDGTVMU-FIBGUPNXSA-N 0.000 claims 1
- GCQNJUUVLOERNW-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(C(F)(F)F)=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(C(F)(F)F)=C1)=O GCQNJUUVLOERNW-FIBGUPNXSA-N 0.000 claims 1
- XUAAPBOKSNXRHP-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(C)=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(C)=C1)=O XUAAPBOKSNXRHP-BMSJAHLVSA-N 0.000 claims 1
- PJILLHUVPVPMOU-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(Cl)=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C(Cl)=C1)=O PJILLHUVPVPMOU-FIBGUPNXSA-N 0.000 claims 1
- ITPVBNRAUWMNBQ-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C)C=C1)=O ITPVBNRAUWMNBQ-FIBGUPNXSA-N 0.000 claims 1
- UVGZUSBIDZZSSK-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C2CC2)C=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(C2CC2)C=C1)=O UVGZUSBIDZZSSK-FIBGUPNXSA-N 0.000 claims 1
- MPWFAXJIIJAKND-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(CC)C=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=C1)=CN=C1NC1=NN(CC)C=C1)=O MPWFAXJIIJAKND-BMSJAHLVSA-N 0.000 claims 1
- OGDJUBOFDSAHGU-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C2=NC=CC=N2)=C1OC)=C1)=CN=C1NC1=NN(C)C(C#N)=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C2=NC=CC=N2)=C1OC)=C1)=CN=C1NC1=NN(C)C(C#N)=C1)=O OGDJUBOFDSAHGU-FIBGUPNXSA-N 0.000 claims 1
- PIQJBUMQUKWCSO-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C2=NC=CC=N2)=C1OC)=C1)=CN=C1NC1=NN(C2CC2)C=C1)=O Chemical compound [2H]C([2H])([2H])NC(C(C(NC(C=CC=C1C2=NC=CC=N2)=C1OC)=C1)=CN=C1NC1=NN(C2CC2)C=C1)=O PIQJBUMQUKWCSO-FIBGUPNXSA-N 0.000 claims 1
- JWMTVOBMIRJQSW-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=C(C=C1C2=NC=C(C(C)(CF)O)C=N2)F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=C(C=C1C2=NC=C(C(C)(CF)O)C=N2)F)=C1OC)=O JWMTVOBMIRJQSW-BMSJAHLVSA-N 0.000 claims 1
- VTZYMZCGZIPQKR-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=C(C=C1C2=NC=C(C(C)O)N=C2)F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=C(C=C1C2=NC=C(C(C)O)N=C2)F)=C1OC)=O VTZYMZCGZIPQKR-BMSJAHLVSA-N 0.000 claims 1
- VEIOCWZLZAIRQO-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(C)(CF)O)C=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(C)(CF)O)C=N2)=C1OC)=O VEIOCWZLZAIRQO-BMSJAHLVSA-N 0.000 claims 1
- BLAVGURTFTYFNL-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(C)(CF)O)N=C2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(C)(CF)O)N=C2)=C1OC)=O BLAVGURTFTYFNL-BMSJAHLVSA-N 0.000 claims 1
- OCLDGZKNVLFGPD-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(CF)(CF)O)C=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C(CF)(CF)O)C=N2)=C1OC)=O OCLDGZKNVLFGPD-FIBGUPNXSA-N 0.000 claims 1
- OWAMVIHMXGKHCG-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C3(CCC3)O)C=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC(C1CC1)=O)=C1)=C1NC(C=CC=C1C2=NC=C(C3(CCC3)O)C=N2)=C1OC)=O OWAMVIHMXGKHCG-FIBGUPNXSA-N 0.000 claims 1
- CUOLLSBAPSOKLD-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=CN(CC)N=N1)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CN(CC)N=N1)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O CUOLLSBAPSOKLD-BMSJAHLVSA-N 0.000 claims 1
- OEOWPRFVTZYISZ-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=CN(CC)N=N1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CN(CC)N=N1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O OEOWPRFVTZYISZ-BMSJAHLVSA-N 0.000 claims 1
- ASJNIYDCMGIZLJ-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=CN(CC)N=N1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=CN(CC)N=N1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O ASJNIYDCMGIZLJ-BMSJAHLVSA-N 0.000 claims 1
- CVAXGWSDDUCVTJ-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C#N)=C1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C#N)=C1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O CVAXGWSDDUCVTJ-FIBGUPNXSA-N 0.000 claims 1
- JVXLJHGMTHCRPQ-HPRDVNIFSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=C(C=C1C(N=C2)=NC=C2F)F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=C(C=C1C(N=C2)=NC=C2F)F)=C1OC)=O JVXLJHGMTHCRPQ-HPRDVNIFSA-N 0.000 claims 1
- OQMZAMZQUCEUGA-HPRDVNIFSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=C(C=C1C2=NC=CC=N2)F)=C1OC)=O OQMZAMZQUCEUGA-HPRDVNIFSA-N 0.000 claims 1
- UXPJRSFNQFIRSD-HPRDVNIFSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O UXPJRSFNQFIRSD-HPRDVNIFSA-N 0.000 claims 1
- JRXAHVZDYYMEPK-HPRDVNIFSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(C)(C)O)=C1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O JRXAHVZDYYMEPK-HPRDVNIFSA-N 0.000 claims 1
- OXJZGPKKXHGQCY-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(N(C)C)=O)=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)C(C(N(C)C)=O)=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O OXJZGPKKXHGQCY-FIBGUPNXSA-N 0.000 claims 1
- DWUCHOZRLLFTMO-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)N=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C)N=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O DWUCHOZRLLFTMO-FIBGUPNXSA-N 0.000 claims 1
- ZEASFAURLIWZST-FIBGUPNXSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C2CC2)C=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(C2CC2)C=C1)=C1)=C1NC(C=CC=C1C(N=C2)=NC=C2F)=C1OC)=O ZEASFAURLIWZST-FIBGUPNXSA-N 0.000 claims 1
- AMTLLNGWRHFIRM-BMSJAHLVSA-N [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(CC)N=C1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O Chemical compound [2H]C([2H])([2H])NC(C(N=NC(NC1=NN(CC)N=C1)=C1)=C1NC(C=CC=C1C2=NC=CC=N2)=C1OC)=O AMTLLNGWRHFIRM-BMSJAHLVSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063016539P | 2020-04-28 | 2020-04-28 | |
| US63/016,539 | 2020-04-28 | ||
| PCT/US2021/029272 WO2021222153A1 (en) | 2020-04-28 | 2021-04-27 | Substituted n-(methyl-d3)pyridazine-3-carboxamide or n-(methyl-d3)-nicotinamide compounds as il-12, il-23 and/or ifnalpha modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523438A JP2023523438A (ja) | 2023-06-05 |
| JPWO2021222153A5 true JPWO2021222153A5 (pt) | 2024-05-10 |
Family
ID=75905074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565827A Pending JP2023523438A (ja) | 2020-04-28 | 2021-04-27 | 置換ヘテロ環式化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230167092A1 (pt) |
| EP (1) | EP4143180A1 (pt) |
| JP (1) | JP2023523438A (pt) |
| KR (1) | KR20230004771A (pt) |
| CN (1) | CN115715287A (pt) |
| WO (1) | WO2021222153A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202233600A (zh) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的ｔｙｋ２抑制劑化合物、藥物組合物及其用途 |
| JP2024510274A (ja) * | 2021-03-16 | 2024-03-06 | アンルイ バイオメディカル テクノロジー （グァンヂョウ） カンパニー リミテッド | アミノヘテロアリール化合物および組成物 |
| WO2022268119A1 (zh) * | 2021-06-22 | 2022-12-29 | 南京明德新药研发有限公司 | 亚磺酰亚胺类化合物及其应用 |
| CN117794911A (zh) * | 2021-07-15 | 2024-03-29 | 南京明德新药研发有限公司 | 含硫/磷的芳基类化合物及其应用 |
| TW202313035A (zh) * | 2021-08-21 | 2023-04-01 | 美商傳達治療有限公司 | Ｊａｋ２抑制劑及其使用方法 |
| IL312330A (en) | 2021-10-25 | 2024-06-01 | Kymera Therapeutics Inc | TYK2 joints and their uses |
| WO2023187182A1 (en) * | 2022-04-01 | 2023-10-05 | Sanofi | Pyrazolopyrazinone compounds, process for their preparation and therapeutic uses thereof |
| WO2023227946A1 (en) * | 2022-05-27 | 2023-11-30 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2914793T3 (es) * | 2012-11-08 | 2022-06-16 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa |
| MX2015005272A (es) * | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
| TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| AU2019373203A1 (en) * | 2018-10-30 | 2021-06-10 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha |
-
2021
- 2021-04-27 WO PCT/US2021/029272 patent/WO2021222153A1/en unknown
- 2021-04-27 EP EP21725357.4A patent/EP4143180A1/en not_active Withdrawn
- 2021-04-27 JP JP2022565827A patent/JP2023523438A/ja active Pending
- 2021-04-27 US US17/997,288 patent/US20230167092A1/en active Pending
- 2021-04-27 CN CN202180043740.1A patent/CN115715287A/zh active Pending
- 2021-04-27 KR KR1020227041017A patent/KR20230004771A/ko active Search and Examination
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4860606B2 (ja) | 糖尿病の処置にｇｌｋアクチベーターとして用いるためのヘテロアリールベンズアミド誘導体 | |
| EP1718624B1 (en) | Benzamide derivatives and their use as glucokinase activating agents | |
| TWI589573B (zh) | 作為ｔｒｋａ激酶抑制劑之吡咯啶基脲及吡咯啶基硫脲化合物 | |
| RU2443699C2 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| JP5518838B2 (ja) | ピロリジノングルコキナーゼアクチベーター | |
| JP2017522346A5 (pt) | ||
| JP2008501673A5 (pt) | ||
| RU2017104510A (ru) | Соединения, активные по отношению к бромодоменам | |
| CN116554152A (zh) | 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺 | |
| CA2554686A1 (en) | Compounds | |
| CN113767105A (zh) | 作为单酰基甘油脂肪酶(magl)的抑制剂的杂环化合物 | |
| JP2021504443A5 (pt) | ||
| JP2014513122A5 (pt) | ||
| JPWO2021222153A5 (pt) | ||
| TW202045498A (zh) | 作為法尼醇x受體調節劑之經取代雙環化合物 | |
| HRP20211262T1 (hr) | Supstituirani spojevi koji sadrže dušik | |
| JP2020522490A5 (pt) | ||
| CN105102449B (zh) | 抗病毒化合物 | |
| WO2022117016A1 (zh) | 羟肟酸酯化合物、其制备方法及其应用 | |
| RU2013152961A (ru) | Изоксазолины в качестве терапевтических агентов | |
| JP2017512184A5 (pt) | ||
| CN114901658A (zh) | 含氮杂环类自分泌运动因子抑制剂及其组合物和用途 | |
| JPWO2021124172A5 (pt) | ||
| EP4263521A1 (en) | Pyrazole derivatives as c-abl inhibitors | |
| RU2023130418A (ru) | Гетероциклические соединения |